Prot #TAC01-HER2-03: A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC T Cells Targeting HER2 in Relapsed or Refractory Solid Tumors (TACTIC-2)

Project: Research project

Project Details

StatusActive
Effective start/end date1/12/23 → 1/12/26

Funding

  • ICON Clinical Research, LLC (Prot #TAC01-HER2-03)
  • Triumvira Immunologics Inc. (Prot #TAC01-HER2-03)